TACI receptor-IgG Fc fragment fusion protein clinical trials
Also written Atacicept and VT-001.
Its developmentBy Merck KGaA, Darmstadt, Germany and Vera Therapeutics, step by step18 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses TACI receptor-IgG Fc fragment fusion protein is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the TACI receptor-IgG Fc fragment fusion protein studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 7 Jul 2026 · TRUTAKNA · BLA 761486 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2008 (4)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2017 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 18 · Other 0
EMD Serono (11) · Vera Therapeutics, Inc. (5) · Merck KGaA, Darmstadt, Germany (1) · EMD Serono Research & Development Institute, Inc. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test TACI receptor-IgG Fc fragment fusion protein.
- Nov 2027Atacicept in Multiple Glomerular DiseasesPhase 2 · Vera Therapeutics, Inc.
Studies
Open first, then newest update. How each study uses TACI receptor-IgG Fc fragment fusion protein is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- Atacicept in Multiple Glomerular DiseasesRecruitingPhase 2Vera Therapeutics, Inc.NCT06983028Written as AtaciceptHow we know
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of AtaciceptEnrolling by invitationPhase 2Vera Therapeutics, Inc.NCT06674577Written as Atacicept 150 mgHow we know
- Monthly Dosing of Atacicept in IgANActive, not recruitingPhase 2Vera Therapeutics, Inc.NCT07020923Written as AtaciceptHow we know
- Atacicept in Subjects With IgA NephropathyActive, not recruitingPhase 3Vera Therapeutics, Inc.NCT04716231Written as AtaciceptHow we know
- Atacicept in Subjects With Active Lupus Nephritis (COMPASS)WithdrawnPhase 3Vera Therapeutics, Inc.NCT05609812Written as AtaciceptHow we know
- Efficacy and Safety of Atacicept in IgA NephropathyTerminatedPhase 2EMD Serono Research & Development Institute, Inc.NCT02808429Written as Atacicept 25 mgHow we know
- Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)TerminatedPhase 2EMD SeronoNCT02070978Written as Atacicept 75 mgHow we know
- Efficacy and Safety of Atacicept in Systemic Lupus ErythematosusCompletedPhase 2EMD SeronoNCT01972568Written as Atacicept 150 mgHow we know
- Atacicept in Multiple Sclerosis Extension Study, Phase IITerminatedPhase 2EMD SeronoNCT00853762Written as Atacicept 25 mgHow we know
- Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)CompletedPhase 2Merck KGaA, Darmstadt, GermanyNCT00664521Written as AtaciceptHow we know
- A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)TerminatedPhase 2EMD SeronoNCT00642902Written as AtaciceptHow we know
- The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus NephritisTerminatedPhase 2/3EMD SeronoNCT00573157Written as AtaciceptHow we know
- Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)CompletedPhase 2/3EMD SeronoNCT00624338Written as Atacicept 75 mgHow we know
- A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)CompletedPhase 2EMD SeronoNCT00430495Written as AtaciceptHow we know
- Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)CompletedPhase 2EMD SeronoNCT00595413Written as Atacicept: with loading doseHow we know
- Atacicept in Subjects With Optic NeuritisTerminatedPhase 2EMD SeronoNCT00624468Written as AtaciceptHow we know
- Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate MofetilTerminatedPhase 1EMD SeronoNCT01369628Written as AtaciceptHow we know
- Atacicept Demonstrating Dose RESponSeWithdrawnPhase 2EMD SeronoNCT01440231Written as AtaciceptHow we know
Codes
What other systems call TACI receptor-IgG Fc fragment fusion protein · ClinicalTrials.gg INT005189
- MeSH (NLM) C524618TACI receptor-IgG Fc fragment fusion proteinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) K3D9A0ICQ3ATACICEPTConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C524618 | TACI receptor-IgG Fc fragment fusion protein | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | K3D9A0ICQ3 | ATACICEPT | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.